Organization: Thermo Fisher Scientific India Pvt Ltd
MD, VP/GM: Amit Chopra
Bioscience Revenue: Rs 875 crore
Thermo Fisher Scientific in India has made deep inroads into the Indian bioscience sector's research and development area. Registering a massive growth, the company garnered Rs 875 crore as annual turnover in 2014-15 as compared to Rs 661 crore in 2013-14. Thermo Fisher Scientific offers an unmatched portfolio of solutions for the life science research and bioprocessing industry including advanced analytical instrumentation, software, life science reagents and media, lab equipment and consumables and service support.
Through the company's premier brands - Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services - Thermo Fisher offers an unmatched combination of innovative technologies, purchasing convenience and comprehensive support
The company's innovative analytical instruments, lab equipment and specialty diagnostics also provide an option in getting accurate results for customers in research, clinical and applied markets.
The major USP of the company is the most comprehensive offering of products and services to allow customers in a range of industries to increase productivity and efficiency. The customized support for researchers such as customized genes, assays, cell lines, kits, user training and onsite support combined with innovative instrumentation have helped company grow its presence in India.
For providing access to the centers-of-excellence, the company has spread application labs and demonstration centers all across the country. This includes analytical demonstration center in Mumbai, the training center at Nasik, the chromatography center-of-excellence for APAC in Ahmedabad, life science application development centers in Delhi and Bengaluru, and a forensics lab in Delhi.
It also opened a customer experience center for cell biology and genomics in Bangalore. It is also planning to add another analytical center in Delhi soon.
As per the company, it invests more than $700 million in R&D annually. The parent company has strengthened bioproduction offering by acquiring Advanced Scientifics (ASI), a global provider of single-use technologies for customized bioprocessing solutions, for $300 million in cash.